ATE239509T1 - Konjugate zur behandlung von prostatakrebs - Google Patents
Konjugate zur behandlung von prostatakrebsInfo
- Publication number
- ATE239509T1 ATE239509T1 AT97946296T AT97946296T ATE239509T1 AT E239509 T1 ATE239509 T1 AT E239509T1 AT 97946296 T AT97946296 T AT 97946296T AT 97946296 T AT97946296 T AT 97946296T AT E239509 T1 ATE239509 T1 AT E239509T1
- Authority
- AT
- Austria
- Prior art keywords
- conjugates
- treatment
- prostate cancer
- prostate
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2922496P | 1996-10-30 | 1996-10-30 | |
GBGB9626309.0A GB9626309D0 (en) | 1996-12-18 | 1996-12-18 | Conjugates useful in the treatment of prostate cancer |
US4292197P | 1997-04-04 | 1997-04-04 | |
GBGB9718160.6A GB9718160D0 (en) | 1997-08-28 | 1997-08-28 | Conjugates useful in the treatment of prostate cancer |
PCT/US1997/019225 WO1998018493A2 (en) | 1996-10-30 | 1997-10-27 | Conjugates useful in the treatment of prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE239509T1 true ATE239509T1 (de) | 2003-05-15 |
Family
ID=27451580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97946296T ATE239509T1 (de) | 1996-10-30 | 1997-10-27 | Konjugate zur behandlung von prostatakrebs |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP0942754B1 (de) |
JP (1) | JP2000509407A (de) |
KR (1) | KR100508199B1 (de) |
AR (1) | AR008907A1 (de) |
AT (1) | ATE239509T1 (de) |
AU (1) | AU726434B2 (de) |
BG (1) | BG64768B1 (de) |
BR (1) | BR9712589A (de) |
CA (1) | CA2268738A1 (de) |
CO (1) | CO4930281A1 (de) |
CZ (1) | CZ155599A3 (de) |
DE (1) | DE69721810T2 (de) |
DK (1) | DK0942754T3 (de) |
DZ (1) | DZ2333A1 (de) |
EA (1) | EA002066B1 (de) |
EE (1) | EE03858B1 (de) |
ES (1) | ES2196374T3 (de) |
HK (1) | HK1024876A1 (de) |
HR (1) | HRP970566A2 (de) |
HU (1) | HUP0000651A3 (de) |
ID (1) | ID21358A (de) |
IL (1) | IL129356A0 (de) |
IS (1) | IS5025A (de) |
NO (1) | NO992069L (de) |
PE (1) | PE17399A1 (de) |
PL (1) | PL333004A1 (de) |
PT (1) | PT942754E (de) |
SK (1) | SK57399A3 (de) |
TR (1) | TR199901485T2 (de) |
TW (1) | TW425286B (de) |
WO (1) | WO1998018493A2 (de) |
YU (1) | YU21399A (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1181092C (zh) * | 1997-12-02 | 2004-12-22 | 麦克公司 | 可用于治疗前列腺癌的缀合物 |
CA2238257A1 (en) * | 1998-05-22 | 1999-11-22 | Universite De Montreal | Endocytosis of amf-r and uses thereof in cancer therapy |
CA2338000C (en) * | 1998-07-17 | 2009-12-15 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Water-soluble 4-thio-maleimido derivatives and methods for their production |
US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
NZ512171A (en) * | 1998-12-11 | 2004-07-30 | Medarex Inc | Prodrug compound comprising a therapeutic agent, an oligopeptide with a non-genetically encoded amino acid, a stabilizing group and optionally a linker group |
GB9924759D0 (en) | 1999-10-19 | 1999-12-22 | Merck Sharp & Dohme | Process for preparing peptide intermediates |
WO2001028593A2 (en) * | 1999-10-19 | 2001-04-26 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
WO2001030804A2 (en) * | 1999-10-27 | 2001-05-03 | Merck & Co., Inc. | Salt form of a conjugate useful in the treatment of prostate cancer |
MXPA02009019A (es) | 2000-03-15 | 2003-02-12 | Du Pont Pharm Co | Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico. |
JP4625637B2 (ja) * | 2002-02-22 | 2011-02-02 | シャイア エルエルシー | 活性物質送達系及び活性物質を保護し投与する方法 |
US20050187147A1 (en) * | 2003-09-22 | 2005-08-25 | Newman Michael J. | Compositions and methods for increasing drug efficiency |
CN100372862C (zh) * | 2003-11-05 | 2008-03-05 | 天津和美生物技术有限公司 | 具有抗癌活性的阿霉素衍生物及其制备方法和应用 |
WO2008067495A2 (en) * | 2006-11-29 | 2008-06-05 | Rutgers, The State University Of New Jersey | Chemotherapeutic conjugates and methods of use |
CN101225094A (zh) | 2007-01-18 | 2008-07-23 | 天津和美生物技术有限公司 | 具有抗癌活性的蒽醌四环类化合物 |
US8642555B2 (en) | 2009-03-09 | 2014-02-04 | Ktb Tumorforschungsgesellschaft Mbh | Prodrugs |
JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
RU2666530C2 (ru) | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
CN107427590B (zh) | 2015-02-02 | 2021-08-31 | 伯明翰大学 | 具有多个t细胞表位的靶向部分肽表位复合物 |
EP3377103B1 (de) | 2015-11-19 | 2021-03-17 | Revitope Limited | Komplementierung eines funktionellen antikörperfragments für ein zwei-komponenten-system zur umgelenkten tötung unerwünschter zellen |
CN116635054A (zh) | 2020-12-22 | 2023-08-22 | 科比欧尔斯公司 | 包括四肽部分的化合物 |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
WO1997014416A1 (en) * | 1995-10-18 | 1997-04-24 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
-
1997
- 1997-10-24 HR HR9718160.6A patent/HRP970566A2/hr not_active Application Discontinuation
- 1997-10-27 HU HU0000651A patent/HUP0000651A3/hu unknown
- 1997-10-27 IL IL12935697A patent/IL129356A0/xx not_active IP Right Cessation
- 1997-10-27 JP JP10520593A patent/JP2000509407A/ja not_active Ceased
- 1997-10-27 WO PCT/US1997/019225 patent/WO1998018493A2/en not_active Application Discontinuation
- 1997-10-27 KR KR10-1999-7003846A patent/KR100508199B1/ko not_active IP Right Cessation
- 1997-10-27 EE EEP199900179A patent/EE03858B1/xx not_active IP Right Cessation
- 1997-10-27 CZ CZ991555A patent/CZ155599A3/cs unknown
- 1997-10-27 SK SK573-99A patent/SK57399A3/sk unknown
- 1997-10-27 DE DE69721810T patent/DE69721810T2/de not_active Expired - Fee Related
- 1997-10-27 PL PL97333004A patent/PL333004A1/xx unknown
- 1997-10-27 CA CA002268738A patent/CA2268738A1/en not_active Abandoned
- 1997-10-27 ES ES97946296T patent/ES2196374T3/es not_active Expired - Lifetime
- 1997-10-27 TR TR1999/01485T patent/TR199901485T2/xx unknown
- 1997-10-27 BR BR9712589-0A patent/BR9712589A/pt not_active Application Discontinuation
- 1997-10-27 EP EP97946296A patent/EP0942754B1/de not_active Expired - Lifetime
- 1997-10-27 DK DK97946296T patent/DK0942754T3/da active
- 1997-10-27 YU YU21399A patent/YU21399A/sh unknown
- 1997-10-27 EA EA199900428A patent/EA002066B1/ru not_active IP Right Cessation
- 1997-10-27 ID IDW990259A patent/ID21358A/id unknown
- 1997-10-27 AU AU51497/98A patent/AU726434B2/en not_active Ceased
- 1997-10-27 PT PT97946296T patent/PT942754E/pt unknown
- 1997-10-27 AT AT97946296T patent/ATE239509T1/de not_active IP Right Cessation
- 1997-10-28 TW TW086115986A patent/TW425286B/zh not_active IP Right Cessation
- 1997-10-28 CO CO97063170A patent/CO4930281A1/es unknown
- 1997-10-29 AR ARP970105032A patent/AR008907A1/es not_active Application Discontinuation
- 1997-10-29 PE PE1997000970A patent/PE17399A1/es not_active Application Discontinuation
- 1997-10-29 DZ DZ970183A patent/DZ2333A1/xx active
-
1999
- 1999-04-13 IS IS5025A patent/IS5025A/is unknown
- 1999-04-29 NO NO992069A patent/NO992069L/no not_active Application Discontinuation
- 1999-05-26 BG BG103436A patent/BG64768B1/bg unknown
-
2000
- 2000-07-07 HK HK00104189A patent/HK1024876A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE239509T1 (de) | Konjugate zur behandlung von prostatakrebs | |
NO20005864D0 (no) | Quinasoler til behandling av hjernesvulst | |
ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
NO971015L (no) | Forbindelser og metoder for behandling av cancer | |
NO984431D0 (no) | FremgangsmÕte for behandling av smerte | |
DE60023982D1 (de) | System zur Behandlung von benigner Prostatahyperplasie | |
IL189132A0 (en) | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer | |
FI971568A (fi) | Menetelmä resistenttien kasvainten hoitamiseksi | |
EP0926955A4 (de) | Konjugate nützlich in die behandlung von prostatakarzinom | |
DE60030554T8 (de) | Verwendungen von et743 zur behandlung von krebs | |
NO20022245D0 (no) | Onkolyttiske kombinasjoner for behandling av cancer | |
IS5035A (is) | Aðferðir til varnar gegn brjóstakrabbameini | |
ATE347372T1 (de) | Vakzine zur behandlung von mycosen | |
DE69729004D1 (de) | Photodynamische therapie zur behandlung von osteosrthritis | |
DZ2665A1 (fr) | Conjugués utiles pour le traitement du cancer de la prostate. | |
NO984446D0 (no) | FremgangsmÕte for behandling av smerte | |
ATE250580T1 (de) | Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie | |
DE69834937D1 (de) | Antibiotika zur behandlung von magengeschwuren | |
NO981822D0 (no) | Anvendelse av proteinet GAX for behandling av cancer | |
NO984189D0 (no) | Fremgangsmåte for behandling av bipolar forstyrrelse | |
DE69806062D1 (de) | Kombinationstherapie zur behandlung von aids | |
ATE204167T1 (de) | Antikonvulsive derivate zur behandlung von psoriasis | |
DE59911556D1 (de) | Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor | |
ZA979655B (en) | Conjugates useful in the treatment of prostate cancer. | |
GB9617941D0 (en) | New approach to the treatment of prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0942754 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |